Welcome to our dedicated page for Arvinas news (Ticker: ARVN), a resource for investors and traders seeking the latest updates and insights on Arvinas stock.
Arvinas, Inc. (NASDAQ: ARVN) is a clinical-stage biotechnology company headquartered in New Haven, Connecticut and focused on targeted protein degradation. Its news flow centers on progress across a pipeline of investigational PROTAC (PROteolysis TArgeting Chimera) protein degraders for oncology and neurodegenerative disorders.
On this ARVN news page, readers can follow company-issued updates on key programs such as vepdegestrant, an investigational PROTAC estrogen receptor degrader for ER+/HER2- advanced or metastatic breast cancer with ESR1 mutations; ARV-393, a BCL6 degrader in Phase 1 trials for relapsed/refractory non-Hodgkin lymphoma; ARV-806, a KRAS G12D degrader for solid tumors including pancreatic, colorectal and lung cancer; and ARV-102, a LRRK2 degrader being studied in Parkinson’s disease and other neurodegenerative conditions.
Typical ARVN news items include clinical data presentations at major scientific meetings, regulatory milestones such as acceptance of the New Drug Application for vepdegestrant by the U.S. Food and Drug Administration, and preclinical results that characterize the activity of new PROTAC candidates. Arvinas also uses press releases to describe collaboration developments with Pfizer, organizational changes, financial updates and other corporate actions disclosed in its SEC filings.
Investors, clinicians and researchers can use this news feed to track how Arvinas’ PROTAC platform is being applied to targets like estrogen receptor, BCL6, KRAS G12D and LRRK2, and to monitor the timing and content of data readouts, regulatory events and partnership announcements related to ARVN.
Arvinas, a clinical-stage biopharmaceutical company, announced that its President and CEO, John Houston, and Chief Scientific Officer, Ian Taylor, will participate in a fireside chat at the Guggenheim Healthcare Talks: 2021 Oncology Day on February 11 at 4:30 p.m. ET. The event will be accessible via a live audio webcast on Arvinas’ website. The company focuses on developing innovative therapies that target disease-causing proteins, with ongoing clinical programs for ARV-110 and ARV-471 aimed at treating advanced forms of prostate and breast cancer respectively.
Arvinas, Inc. (Nasdaq: ARVN) announced the full exercise of the underwriter's option to purchase additional shares in its recent public offering, resulting in a total sale of 6,571,428 shares. This offering has generated approximately $431.9 million in net proceeds. Goldman Sachs & Co. LLC and Piper Sandler & Co. managed the offering, with additional support from Cantor Fitzgerald & Co. and BMO Capital Markets. The press release clarifies this is not an offer to sell or solicit any securities unlawfully.
Arvinas, Inc. (Nasdaq: ARVN) has priced a public offering of 5,714,286 shares of its common stock at $70.00 per share, with an option for underwriters to purchase an additional 857,142 shares. This offering is expected to close around December 18, 2020, subject to standard conditions. The funds raised will support Arvinas' efforts in developing targeted protein degradation therapies through its PROTAC® platform, which focuses on treating severe diseases. Goldman Sachs and Piper Sandler are leading the underwriting process.
Arvinas, Inc. (Nasdaq: ARVN) has announced a public offering of $250 million of its common stock, with an additional $37.5 million option for underwriters. Goldman Sachs & Co. LLC and Piper Sandler & Co. are the joint book-running managers. This offering is part of a planned strategy to support Arvinas’ ongoing clinical programs, including its two key candidates: ARV-110 for prostate cancer and ARV-471 for breast cancer. The offering is subject to market conditions and investor interest.
Arvinas, a clinical-stage biopharmaceutical company, announced clinical updates on its PROTAC® protein degraders: ARV-471 and ARV-110. ARV-471 shows potential for best-in-class safety and efficacy in patients with ER+/HER2- breast cancer, demonstrated by a 42% clinical benefit rate and confirmed partial responses. ARV-110 displays anti-tumor activity in men with metastatic castration-resistant prostate cancer, achieving a 40% PSA50 response rate. Both compounds are well tolerated, with ongoing trials expected to advance in 2021, including combination studies.
Arvinas, a clinical-stage biotechnology company, will host a live webcast on December 14, 2020, at 8:00 a.m. ET to present updates on its clinical programs for ARV-471 and ARV-110. The presentation will cover the Phase 1 dose escalation studies for ARV-471 in ER positive/HER2 negative breast cancer and ARV-110 for metastatic castrate-resistant prostate cancer, along with details about the newly initiated Phase 2 dose expansion study for ARV-110.
Arvinas, a clinical-stage biotechnology company focused on targeted protein degradation, will present at two virtual investor conferences. The first is the Piper Sandler 32nd Annual Virtual Healthcare Conference on December 1, 2020, featuring a pre-recorded chat with management. The second conference is the 3rd Annual Evercore ISI HealthCONx Virtual Conference on December 3, 2020, with live participation from key executives. Arvinas is dedicated to developing therapies for debilitating diseases using its proprietary PROTAC® platform, targeting proteins causing various conditions.
Arvinas, a clinical-stage biopharmaceutical firm, announced significant updates in its latest press release. The company has initiated Phase 2 dosing for ARV-110 and continues dose escalation for ARV-110 and ARV-471 trials. A collaboration with Pfizer will lead to a Phase 1b trial combining ARV-471 with Ibrance, expected to start fourth quarter 2020. Financial results for Q3 2020 highlighted a net loss of $30.8 million, an increase from $17.7 million in Q3 2019, amid rising R&D expenses of $30.0 million. Cash reserves were $248.6 million, sufficient to support operations into 2022.
Arvinas, Inc. (Nasdaq: ARVN) announced significant updates to its preclinical pipeline, revealing five new programs targeting oncology, immuno-oncology, and neuroscience. The company aims to enhance its leadership in targeted protein degradation with its PROTAC® Discovery Engine. Key targets include BCL6, KRAS, Myc, HPK1, and mHTT, with plans to file INDs by 2022 and 2023. Clinical trials are ongoing for ARV-110 and ARV-471, with data updates expected in Q4 2020. This expansion underscores Arvinas' commitment to addressing high unmet medical needs in various disease areas.
Arvinas, a clinical-stage biotechnology company (Nasdaq: ARVN), will have its President and CEO, John Houston, Ph.D., present at the 3rd Annual Targeted Protein Degradation Summit on October 14-15, 2020. The session, titled "The Promise of PROTAC® Protein Degraders: What’s Next for Arvinas’ Pipeline & Platform," will showcase advancements in Arvinas' PROTAC® technology and introduce new pipeline programs. The company focuses on developing therapies that degrade disease-causing proteins, with two clinical-stage programs targeting advanced prostate and breast cancers.
FAQ
What is the current stock price of Arvinas (ARVN)?
What is the market cap of Arvinas (ARVN)?
